Stories and Viewpoints
Join us as we explore the gears that power our business model in our ongoing series #DiscoverViatris
July 14, 2021
Spanning 5 billion people around the world, Viatris’ Emerging Markets segment covers 125 countries and a diverse range of socioeconomic conditions and healthcare needs. In fact, 85% of deaths from non-communicable diseases (NCDs) happen in these countries,1 while infectious diseases also run rampant, with 95% of tuberculosis patients2 and more than 12 million people living with HIV who don’t have access to treatment.3 Addressing these challenges will have profound implications for patients and accelerate worldwide progress towards global health goals and prosperity. Here are five things to know about Viatris’ Emerging Markets segment:
1 Viatris brings together a comprehensive portfolio and vast supply chain that positions us to meet patient needs around the world. We are one of the world’s largest manufacturers of active pharmaceutical ingredients (API),4 and our 1,400 approved molecules treat a variety of diseases across a broad range of major therapeutic areas.5 Our Emerging Markets portfolio addresses a broad range of therapeutic areas, with over half of it focusing on NCD treatments and a third on antiretroviral drugs.
2 Each of our 5,000 colleagues play a part in our seamless and end-to-end product manufacturing, distribution and innovation process, bringing products from the minds of our scientists to the labs that create them, from the plants to the pharmacies and clinics, to the hands of those who need them most. We produce a total of 80 billion doses of medicine a year,6 ranking us among the top five companies to which certain Emerging Markets look for cardiovascular, pain, antiretroviral and a variety of other medicines.7
3 We partner with organizations on various global public health issues to reach more patients. In our Emerging Markets, we have worked with TB Alliance to provide affordable treatment for multi-drug-resistant tuberculosis to low and middle-income countries, and have collaborated with various other NGOs to provide antiretroviral drugs to patients living with HIV. Most recently, under Egypt’s Tahya Misr program, we sponsored approximately 1 million hepatitis C screening kits at low cost. We also partnered with various local specialist companies and governments across our Emerging Markets to provide access to access to SARS-CoV-2 Antibody Test (Lateral Flow Method), which helped increase the number of tests being conducted across the region and helped governments to closely monitor the progress of COVID-19.
In addition, Viatris’ own Emerging Markets NCD Think Tank is dedicated to improving NCD outcomes, advocating for stakeholders’ support and co-designing approaches to beyond-the-pill solutions.8
4 Along with relief efforts, we also aim to improve local capacities to address the healthcare needs of the communities in which we operate. We provide tailored programs to train local healthcare professionals and assist with further research. Our advocacy efforts have also led and accelerated positive change in India, our policy teams helped secure the manufacturing of oxytocin for domestic use, significantly reducing the risk of childbirth complications for both mothers and children.
5 We work to ensure that patients in Emerging Markets have access to the right treatments at the right time. This work is driven by our mission to empower people everywhere to live healthier at every stage of life. We strive to make a positive impact so that those living in Emerging Markets can live healthier and play their own part in helping their nations grow and prosper.
1. WHO, “Noncommunicable diseases fact sheet.”
2. WHO, “Tuberculosis fact sheet”
3. UNAIDS, “UNAIDS calls on countries to step up global action and proposes bold new HIV targets for 2025”
4. Viatris, “Active Pharmaceutical Ingredients.”
5. Viatris press release, “Viatris Inc. Launches as a New Kind of Healthcare Company, Positioned to Meet the World's Evolving Healthcare Needs.”
6. DCAT Value Chain Insights, “Generic Drugs: What’s Next for Viatris?”
7. “Viatris Investor Day” presentation, quoting IQVIA MIDAS MAT Q3 2020
8. Viatris, “Partnerships.”